{
  "guideline": {
    "id": "PA166124619",
    "name": "Annotation of CPIC Guideline for tacrolimus and CYP3A5",
    "source": "CPIC",
    "version": 38,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166124619",
    "relatedChemicals": [
      {
        "id": "PA451578",
        "name": "tacrolimus",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA131",
        "name": "cytochrome P450 family 3 subfamily A member 5",
        "symbol": "CYP3A5"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298514",
      "name": "Recommendation PA166298514",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451578",
          "name": "tacrolimus",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061116,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP3A5: n/a"
      ],
      "lookupKey": {
        "CYP3A5": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298510",
      "name": "Recommendation PA166298510",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451578",
          "name": "tacrolimus",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061112,
        "html": "<p>Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function). Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose, and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP3A5: Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations."
      ],
      "lookupKey": {
        "CYP3A5": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298511",
      "name": "Recommendation PA166298511",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451578",
          "name": "tacrolimus",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061113,
        "html": "<p>Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function).Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP3A5: Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations."
      ],
      "lookupKey": {
        "CYP3A5": "Possible Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298512",
      "name": "Recommendation PA166298512",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451578",
          "name": "tacrolimus",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061114,
        "html": "<p>Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors (e.g., medication interactions, or hepatic function).Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP3A5: Lower dose-adjusted trough concentrations of tacrolimus and decreased chance of achieving target tacrolimus concentrations."
      ],
      "lookupKey": {
        "CYP3A5": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298513",
      "name": "Recommendation PA166298513",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451578",
          "name": "tacrolimus",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061115,
        "html": "<p>Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>This recommendation includes the use of tacrolimus in kidney, heart, lung and hematopoietic stem cell transplant patients, and liver transplant patients where the donor and recipient genotypes are identical. Typically with other CYP enzymes, a normal metabolizer would be classified as having normal metabolism, and therefore, the drug dose would not change based on the patient’s genotype. However, in the case of CYP3A5 and tacrolimus, a CYP3A5 expresser (i.e., CYP3A5 normal metabolizer or intermediate metabolizer) would require a higher recommended starting dose and the CYP3A5 non-expresser (i.e., poor metabolizer) would require the standard recommended starting dose.</p>\n"
      },
      "implications": [
        "CYP3A5: Higher (\"normal\") dose-adjusted trough concentrations of tacrolimus and increased chance of achieving target tacrolimus concentrations."
      ],
      "lookupKey": {
        "CYP3A5": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "25801146",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.",
      "authors": [
        "Birdwell K A",
        "Decker B",
        "Barbarino J M",
        "Peterson J F",
        "Stein C M",
        "Sadee W",
        "Wang D",
        "Vinks A A",
        "He Y",
        "Swen J J",
        "Leeder J S",
        "van Schaik Rhn",
        "Thummel K E",
        "Klein T E",
        "Caudle K E",
        "MacPhee I A M"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2015
    }
  ],
  "version": "2023-12-19-10-38"
}